Search results for "Isoniazid"

showing 4 items of 24 documents

Isoniazid cocrystallisation with dicarboxylic acids: vapochemical, mechanochemical and thermal methods

2016

Cocrystallisation with a series of related compounds allows for the exploration of trends and limitations set by structural differences between these compounds. In this work, we investigate how the length of a dicarboxylic acid influences the outcome of cocrystallisation with isoniazid. We have performed a systematic study on the mechanochemical, thermal and solvent vapour-assisted cocrystallisation of aliphatic dicarboxylic acids (C3–C10) with isoniazid. Our results demonstrate that the rate of mechanochemical and vapour-assisted cocrystallisation depends on the acid chain length and shows alternation between odd- and even-chain acids. The results of thermal cocrystallisation showed that t…

chemistry.chemical_classificationIsoniazid02 engineering and technologyGeneral Chemistry010402 general chemistry021001 nanoscience & nanotechnologyCondensed Matter Physics01 natural sciences0104 chemical sciencesSolventChain lengthDicarboxylic acidchemistryMelting pointmedicineOrganic chemistryGeneral Materials Science0210 nano-technologyEutectic systemThermal methodsmedicine.drugCrystEngComm
researchProduct

A Case of Epididymo-orchitis after intravesical bacille Calmette-Guérin therapy for superficial bladder carcinoma in a patient with latent tuberculos…

2016

Background: Intravesical instillation of bacille Calmette-Guérin (BCG) has been established as efficient therapy for superficial bladder carcinoma. Overall, intravesical BCG is well tolerated and results in complications of less than 5 %. However, adverse effects such as granulomatous prostatitis, pneumonitis, hepatitis, sepsis, and hypersensitivity reactions may occur. The reported rate for tuberculous orchitis after BCG intravesical therapy is 0.4 %. Findings: We report a case of monolateral tuberculous orchitis occurring one month after the second course of intravescical instillation of bacille Calmette-Guérin in a patient with proven superficial bladder carcinoma and latent tuberculosis…

medicine.medical_specialtyCancer ResearchComplicationsSettore MED/17 - Malattie InfettiveEpidemiologyBladder030232 urology & nephrologyUrologyShort ReportInfectious DiseaseGastroenterologySepsis03 medical and health sciences0302 clinical medicineInternal medicinemedicineGranulomatous prostatitisBladder; Calmette; Complications; Guérin; Intravesical; Infectious Diseases; Oncology; Epidemiology; Cancer ResearchPneumonitisHepatitisLatent tuberculosisbusiness.industryIntravesicalIsoniazidmedicine.diseaseInfectious DiseasesOncology030220 oncology & carcinogenesisOrchitisSuperficial Bladder CarcinomabusinessComplicationGuérinmedicine.drugCalmetteInfectious Agents and Cancer
researchProduct

Serum isoniazid concentration in the patients as an indicator of the effectiveness and toxicity of tuberculosis treatment

2019

Introduction The low serum concentration of the anti-tuberculosis (TB) drugs in TB patients is observed quite often, but the significance of this phenomenon remains controversial. Aim The aim of the presented research was to clarify the association between isoniazid concentration and TB-treatment outcomes. Material and methods Blood samples were obtained from 86 patients with newly diagnosed pulmonary TB at Odessa Regional TB Hospital in 2015. The level of isoniazid in blood was measured 2 h, 4 h, 6 h, and 24 h after the administration of isoniazid. The medical records of the enrolled patients at the beginning and at the end of the in-patient treatment, and the activity of the biochemical i…

medicine.medical_specialtyconcentrationisoniazidTuberculosistreatmentbusiness.industryIsoniazidtoxicityGeneral Medicinemedicine.diseaseGastroenterologytuberculosisInternal medicineToxicitymedicinebusinessmedicine.drugPolish Annals of Medicine -Rocznik Medyczny
researchProduct

Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection

2022

Background Some biologics for psoriasis, especially anti-tumor necrosis factor (TNF)-alpha therapies, may re-activate latent tuberculosis (TBC) infection with consequent morbidity and mortality. However, there is a low reported incidence of conversion to positive TBC status among patients with psoriasis treated with second-generation biologic therapies, particularly anti-interleukin (IL)-17 therapies such as secukinumab. Objectives To evaluate the safety profile of secukinumab in psoriasis patients with latent TBC infection. Methods Real-life data were collected by retrospective chart review on patients with moderate-to-severe psoriasis who showed positivity for TBC screening at baseline an…

reactivationBiologicpsoriasis.latent tuberculosis infectionsecukinumabchemoprophylaxisDermatologyBiologicsBiologics; chemoprophylaxis; latent tuberculosis infection; psoriasis; reactivation; secukinumab.Antibodies Monoclonal HumanizedSeverity of Illness IndexTreatment OutcomeLatent TuberculosisIsoniazidHumansPsoriasisTuberculosisRifampinchemoprophylaxiRetrospective Studiespsoriasi
researchProduct